Bruker Corp Stock Price, News & Analysis

Bruker Corporation (Nasdaq: BRKR) has received US FDA clearance for the MBT Sepsityper Kit US IVD, designed for rapid identification of over 425 microorganisms from positive blood cultures. This innovative kit, utilized with the MALDI Biotyper CA System, significantly reduces the time-to-result by up to 24 hours compared to traditional methods, enhancing patient outcomes in suspected sepsis cases. Clinical experts highlight its affordability and efficiency, potentially improving antibiotic stewardship and healthcare resource management.

Bruker Corporation (Nasdaq: BRKR) has launched the FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel for simultaneous detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). This CE-IVD labeled kit can process up to 96 PCR results in under two hours and has demonstrated 100% sensitivity and specificity in validation tests. The panel also accommodates saliva samples, offering convenience and efficiency for clinical labs. The launch reflects Bruker’s commitment to enhancing diagnostic capabilities during the winter virus season.

Bruker Corporation (Nasdaq: BRKR) will take part in the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 2:05 PM GMT (9:05 AM EST). CFO Gerald Herman will engage in an analyst Q&A session during the event. A live audio webcast can be accessed on Bruker's Investor Relations website, with a replay available for 30 days post-event. Bruker focuses on advancing scientific discovery through high-performance instruments and analytical solutions across various fields, enhancing research in life sciences and clinical applications.

Bruker Corporation (Nasdaq: BRKR) reported Q3 2020 revenues of $511.4 million, down 1.9% year-over-year. Organic revenue declined 4.6%, attributed to decreased demand from academic and industrial sectors amid the COVID-19 pandemic. Q3 GAAP operating income was $81.2 million with a margin of 15.9%, while non-GAAP operating income was $94.9 million, marking an 18.6% margin. Year-to-date revenues totaled $1.36 billion, a 7.7% decline. FY 2020 guidance remains suspended due to pandemic-related impacts.

Bruker Corporation (Nasdaq: BRKR) has introduced the Vutara VXL Super-Resolution Fluorescence Microscope, aimed at enhancing affordable, super-resolution imaging in biological research. This innovative system employs Bruker’s leading single-molecule localization technology, facilitating advanced studies of DNA, RNA, and proteins, as well as complex biological structures. Key features include high spatial resolution, multiplexing capabilities, and integrated analytical software, making it suitable for various research applications. The company aims to broaden access to 3D microscopy for the scientific community, potentially advancing cellular biology research.

Bruker Corporation (Nasdaq: BRKR) will release its third quarter 2020 financial results on November 2, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results and current business trends. Investors can participate via webcast or telephone. Pre-registration is available to streamline entry. A replay of the call will be accessible until December 2, 2020, using the provided conference number.

Bruker Corporation (Nasdaq: BRKR) has launched the Fourier™ 80, an 80 MHz benchtop FT-NMR spectrometer, in Europe. The device features gradient spectroscopy and an optional CTC PAL^® sample changer, enhancing throughput and efficiency. With a novel 80 MHz permanent magnet, it eliminates the need for cryogens and cooling. The new model offers 20% improved resolution, making it suitable for chemistry labs and educational purposes. Dr. Falko Busse emphasizes its role in democratizing FT-NMR applications, enabling greater accessibility for both research and teaching.

Bruker Corporation (Nasdaq: BRKR) has acquired the Integrated Proteomics Pipeline (IP2) developed by Integrated Proteomics Applications Inc. This acquisition enhances Bruker's bioinformatics capabilities, supporting its innovative CCS-enabled 4D-Proteomics™. The IP2 allows fast, scalable data processing, increasing confidence in protein identification and quantification. Bruker will establish a San Diego-based bioinformatics team led by Robin Park, enhancing collaborations with the Yates Lab. Financial terms of the acquisition remain undisclosed.